Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Department of Veterans Affairs |
---|---|
Information provided by: | Department of Veterans Affairs |
ClinicalTrials.gov Identifier: | NCT00032487 |
This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 25% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.
Condition | Intervention | Phase |
---|---|---|
Type 2 Diabetes Mellitus |
Drug: Insulin Drug: Glimepiride Drug: Rosiglitazone Drug: Metformin |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Dose Comparison, Parallel Assignment, Safety/Efficacy Study |
Official Title: | CSP#465 - Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT) |
Enrollment: | 1791 |
Study Start Date: | December 2000 |
Study Completion Date: | May 2008 |
Primary Completion Date: | May 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
Standard glycemic control to maintain HbA1c between 8.0-9.0%.
|
Drug: Insulin Drug: Glimepiride Drug: Rosiglitazone Drug: Metformin |
2: Experimental
Intensive glycemic control lower HbA1c below 7.0%.
|
Drug: Insulin Drug: Glimepiride Drug: Rosiglitazone Drug: Metformin |
Ages Eligible for Study: | 40 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with type 2 DM who are no longer responsive to maximum dose of one or more oral agents.
Exclusion Criteria:
Study Chair: | Carlos Abraira, MD | VA Medical Center, Miami |
Responsible Party: | Department of Veterans Affairs ( Abraira, Carlos - Study Chair ) |
Study ID Numbers: | 465 |
Study First Received: | March 21, 2002 |
Last Updated: | August 29, 2008 |
ClinicalTrials.gov Identifier: | NCT00032487 |
Health Authority: | United States: Federal Government; United States: Food and Drug Administration |
DM glycemic control insulin type 2 diabetes mellitus |
Glimepiride Metabolic Diseases Metformin Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases |
Endocrinopathy Metabolic disorder Glucose Metabolism Disorders Rosiglitazone Insulin |
Hypoglycemic Agents Immunologic Factors Therapeutic Uses Physiological Effects of Drugs |
Cardiovascular Agents Anti-Arrhythmia Agents Immunosuppressive Agents Pharmacologic Actions |